ASCO 2021 : Cellworks Singula™ Delivers Superior OS and DFS Predictions for Brain Cancer Patients in myCare-022-03 Clinical Trial

Personalized Therapy Biosimulation Using Multi-Omic Data Accurately Predicts Clinical…

ASCO 2021 : Cellworks CBM Clinical Study Identifies Novel Biomarkers for ATRA Benefit and Failure in AML Patients

Personalized Therapy Biosimulation Predicts with 100% Accuracy ATRA Non-Response in…

ASCO 2021 : Cellworks Singula™ Accurately Predicts Clinical Outcome from Treatments in Patients with NSCLC

Personalized Therapy Biosimulation Using Multi-Omic Data Predicts OS and PFS for NSCLC…

ASH 2020 : Cellworks Personalized Biosimulation Clinical Trials Achieve 90% Therapy Response Prediction Accuracy for AML and MDS Patients

myCare-020-01 and myCare-020-02 studies show Cellworks Singula™ has high accuracy and…

ASH 2020 : Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy

myCare-021-01 study found CBM has high accuracy for predicting therapy response in APL…

ASH 2020 : Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies

myCare-021-02 study discovers patient-specific resistance mechanisms that can inform…

ASH 2020 : Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with
Monosomy 7

myCare-021-04 study finds genetic signatures associated with 100% remission rate from…

ASCO 2020 : myCare Clinical Studies Show Cellworks Singula™Achieves Superior Therapy Response Predictions for Brain Cancer Patients

Cellworks Multi-omics Biosimulation Delivers GBM and LGG Survival Predictors Above and…

ASCO 2020 : Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments

myCare Studies Show Cellworks Multi-omics Biosimulation is a Superior Predictor of…

ASCO 2020 : Cellworks Singula™ Predicts Personalized Therapy Responses for Pancreatic Cancer Patients with 94% Accuracy

myCare Study Shows Cellworks Multi-omics Biosimulation is a Superior Predictor of…

Blood Advances Publishes Cellworks Prospective Genomic Biosimulation Study that Predicts Cancer Therapy Response with 90% Accuracy

Study Uses NGS Data with Biosimulation to Predict Drug Response in AML and MDS…

ASCO 2019 : Cellworks myCare™ Clinical Trial Transforms NGS Data into Personalized Cancer Therapy Actions

New Trial Biosimulates Efficacy of Cancer Therapies Using Molecular Genetic Aberration…

ASH 2018 : Cellworks Study Predicted Non-Response to Azacitidine in MDS Patients with 100% Accuracy using AI-Driven Biosimulation

Analysis Uncovered Possible Mechanisms for AZA Resistance that could be Targeted to…

ASH 2018 : Cellworks AI-Driven Biosimulation Predicted Chemo-resistance in AML and MDS Patients with 90% Accuracy

Prospective Study Successfully Identified Mechanisms for AML…

Cellworks to Present 10 Abstracts at 2018 American Society of Hematology Annual Meeting

ASH Abstracts Reveal How AI-Driven Biosimulation Technology Predicts Drug Response in…

Former UnitedHealth Group Cancer Director Dr. Lee Newcomer Joins Cellworks Board of Directors

Leading Precision Medicine Company Adds to Prestigious Board of Directors, which…

Dr. Allen Lichter Joins Cellworks Group Board of Directors

Former CEO of ASCO Elected to Board of Leading Precision Medicine Company

…